Different forms of helper tolerance to carcinoembryonic antigen: Ignorance and regulation

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4528-4537

  Pickford, Wendy J ^a   Watson, Angus J M ^b   Barker, Robert N ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD45RA ANTIGEN; CYTOKINE; INTERLEUKIN 10; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNOLOGY;

ADULT; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BLOOD DONORS; CARCINOEMBRYONIC ANTIGEN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 34547683572     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0721     Document Type: Article

References (45)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
2. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res 2005;123:61-88.
3. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
4. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
5. Nossal GJV, McHeyzer-Williams MG, Pulendran B, McLean M, Lalor PA, Karvelas M. Immunological tolerance revisited in the molecular era. In: Gergely J, Benczur M, Erdie A, Falus A, Fust G, Medgyesi G, Petranyi G, Rajnavolgyi E, editors. Progress in immunology VIII. Berlin: Springer-Verlag; 1993. p.3-9.
6. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viralan tigen transgenic mice. Cell 1991;65:305-17.
7. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
8. + suppressor T cells. Immunol Rev 2001;182:58-67.
9. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
10. + T cells and the control of autoimmune disease. Curr Opin Immunol 2004;16:695-701.
11. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
12. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol20 02;20:2197-207.
13. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions, and expression in normalan d malignant tissues. Semin Cancer Biol1999;9:67-81.
14. Mitchell EP. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol 1998;25 Suppl 11:S12-20.
15. Kuroki M, Arakawa F, Yamamoto H, Shimura H, Ikehara Y, Matsuoka Y. Active production and membrane anchoring of carcinoembryonic antigen observed in normal colon mucosa. Cancer Lett 1988;43:151-7.
16. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007;13:727-32s.
17. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-65.
18. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794-803.
19. + T lymphocytes: a criticalc omponent of antitumor immunity. Cancer Invest 2005;23:413-9.
20. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-47.
21. Zbar AP, Lemoine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA. Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target. Br J Cancer 1998;77:683-93.
22. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439-49.
23. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90.
24. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int JCancer 1999;80:92-7.
25. Kawashima I, Hudson SJ, Tsai V, et al. The multiepitope approach for immunotherapy for cancer : identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1-14.
26. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999;59:431-5.
27. Ruiz M, Kobayashi H, Lasarte JJ, et al. Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res 2004;10:2860-7.
28. Campi G, Crosti M, Consogno G, et al. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003;63:8481-6.
29. + T cells of lung cancer patients. J Immunol2 006;176:5093-9.
30. Kobayashi H, Omiya R, Ruiz M, et al . Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25.
31. Shen L, Schroers R, Hammer J, Huang XF, Chen SY. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother 2004;53:391-403.
32. Ullenhag GJ, Fagerberg J, Strigard K, Frodin JE, Mellstedt H. Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA. Cancer Immunol Immunother 2004;53:331-7.
33. Barker RN, Elson CJ. Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells in vitro. Eur J Immunol1 994;24:1578-82.
34. Plebanski M, Saunders M, Burtles SS, Crowe S, Hooper DC. Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms. Immunology 1992;75:86-91.
35. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003;170:6183-9.
36. Devereux G, Hall AM, Barker RN. Measurement of T-helper cytokines secreted by cord blood mononuclear cells in response to allergens. J Immunol Methods 2000;234:13-22.
37. Hall AM, Ward FJ, Vickers MA, Stott LM, Urbaniak SJ, Barker RN. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood 2002;100:4529-36.
38. Elson CJ, Barker RN. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr Opin Immunol 2000;12:664-9.
39. Barker RN, Hall AM, Standen GR, Jones J, Elson CJ. Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia. Blood 1997;90:2701-15.
40. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
41. Cairns LS, Phelps RG, Bowie L, et al. The fine specificity and cytokine profile of T-helper cells responsive to the α3 chain of type IV collagen in Goodpasture's disease. J Am Soc Nephrol 2003;14:2801-12.
42. Phelps RG, Jones VL, Coughlan M, Turner AN, Rees AJ. Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences. J Biol Chem 1998;273:11440-7.
43. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape fromcentral tolerance. Immunity 1995;3:407-15.
44. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-62.
45. Elson CJ, Barker RN, Thompson SJ, Williams NA. Immunologically ignorant autoreactive T cells, epitope spreading, and repertoire limitation. Immunol Today 1995;16:71-6.